Core A (Administrative Core) will provide all the logistic, scientific, managerial, regulatory and financial support necessary to facilitate and coordinate the studies described in this Consortium. The Administrative Core will ensure that all common and project-specific efforts function optimally and adhere to the timelines described in Program Overview and in the individual projects of this proposal. The Core will organize conference calls every two weeks among Project leaders and other relevant personnel, facilitate regular in-person meetings, maintain regulatory approvals, provide fiscal and logistic oversight, and coordinate meetings with the Scientific Advisory Board and DAIDS Program Officials. The Core will also establish a Scientific Leadership Committee, the primary decision-making body of the Consortium, whose roles include determining allocations of primate resources to individual experiments and consulting in the design of these experiments. The Core will coordinate four annual meetings of this Leadership Committee. The Administrative Core and Scientific Leadership Committee will ensure that all the studies and resources are applied to the primary goals of this proposal. These are: ? to establish the therapeutic utility in HIV-1 infection of a cocktail of antibody or antibody-like entry inhibitors delivered through recombinant adeno-associated virus (AAV) vectors, and ? to identify principles, protocols, and therapeutics directly applicable to human clinical trials. We will support these goals in five Specific Aims: 1. To coordinate communications, interactions, and operations among investigators. Projects, and Cores to facilitate the overall progress and promote the goals of this program project. 2. To coordinate four annual meetings of the Scientific Leadership committee. 3. To ensure and maintain regulatory compliance. 4. To provide detailed financial oversight and management. 5. To coordinate meetings with the Scientific Advisory Board.
The Administrative core is responsible for all fiscal, regulatory, and administrative aspects of this proposal. In addition, it will facilitate communication among Project Leaders, and organize meetings of the Leadership and Scientific Advisory Committees. These activities will promote the broad aim of this Program Project: to establish the therapeutic utility in an ongoing HIV-1 infection of specific cocktails of AAV-delivered antivirals.
|Wang, Dan; Zhong, Li; Nahid, M Abu et al. (2014) The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv 11:345-64|
|Wang, Dan; Gao, Guangping (2014) State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov Med 18:67-77|
|Quinlan, Brian D; Joshi, Vinita R; Gardner, Matthew R et al. (2014) A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and coreceptor-binding sites of gp120. J Virol 88:3353-8|
|Wang, Dan; Gao, Guangping (2014) State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. Discov Med 18:151-61|
|Gao, Kai; Li, Mengxin; Zhong, Li et al. (2014) Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side-Effects. Mol Ther Methods Clin Dev 1:20139|
|Quinlan, Brian D; Gardner, Matthew R; Joshi, Vinita R et al. (2013) Direct expression and validation of phage-selected peptide variants in mammalian cells. J Biol Chem 288:18803-10|
|Stoica, Lorelei; Ahmed, Seemin S; Gao, Guangping et al. (2013) Gene transfer to the CNS using recombinant adeno-associated virus. Curr Protoc Microbiol Chapter 14:Unit14D.5|
|Gruntman, Alisha M; Bish, Lawrence T; Mueller, Christian et al. (2013) Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus. Curr Protoc Microbiol Chapter 14:Unit 14D.3|
|Venkatesh, Aditya; Ma, Shan; Langellotto, Fernanda et al. (2013) Retinal gene delivery by rAAV and DNA electroporation. Curr Protoc Microbiol Chapter 14:Unit 14D.4|
|Ahmed, Seemin Seher; Li, Jia; Godwin, Jonathan et al. (2013) Gene transfer in the liver using recombinant adeno-associated virus. Curr Protoc Microbiol Chapter 14:Unit14D.6|